Distinction between early and late ovarian hyperstimulation syndrome

Fertility and Sterility

Volumn 73, Issue 5, 2000, Pages 901-907

  Mathur, Rajneesh S ^a   Akande, A Valentine ^a   Keay, Stephen D ^a   Hunt, Linda P ^b   Jenkins, Julian M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b St Michael's Hill   (United Kingdom)

Author keywords

IVF complications; OHSS; Risk prediction; Severity

Indexed keywords

GONADOTROPIN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ESTRADIOL BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OOCYTE; OVARY CYCLE; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; PREGNANCY RATE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0034002055     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0015-0282(00)00492-1     Document Type: Article

References (21)

1. Dahl Lyons C.A., Wheeler C.A., Frishman G.N., Hackett R.J., Seifer D.B., Haning R.V. Early and late presentation of the ovarian hyperstimulation syndrome two distinct entities with different risk factors . Hum Reprod. 9:1994;792-799.
2. Mathur R.S., Joels L.A., Akande A.V., Jenkins J.M. The prevention of ovarian hyperstimulation syndrome. Br J Obstet Gynecol. 103:1996;740-746.
3. Asch R.H., Li H., Balmaceda J.P., Weckstein L.N., Stone S.C. Severe ovarian hyperstimulation syndrome in assisted reproductive technology definition of high risk groups . Hum Reprod. 6:1991;1395-1399.
4. Morris R.S., Paulson R.J., Sauer M.V., Lobo R.A. Predictive value of serum estradiol concentrations and oocyte number in severe ovarian hyperstimulation syndrome. Hum Reprod. 10:1995;811-814.
5. Hull M.G.R., Armatage R.J., McDermott A. Use of follicle-stimulating hormone alone (urofollitrophin) to stimulate the ovaries for assisted conception after pituitary desensitization. Fertil Steril. 62:1994;997-1003.
6. Golan A., Ron-El R., Herman A., Soffer Y., Weinraub Z., Caspi E. Ovarian hyperstimulation syndrome an update review . Obstet Gynecol Surv. 44:1989;430-440.
7. Conover W.J. Practical nonparametric statistics. 1980;John Wiley and Sons, New York.
8. Jaeschke R., Guyatt G.H., Sackett D.L. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA. 271:1994;703-707.
9. Delvigne A., Demoulin A., Smitz J., Donnez J., Koninckx P., Dhont M., et al. The ovarian hyperstimulation syndrome in in-vitro fertilization a Belgian multicentric study. I. Clinical and biologic features . Hum Reprod. 8:1993;1353-1360.
10. MacDougall M.J., Tan S.L., Jacobs H.S. In-vitro fertilization and the ovarian hyperstimulation syndrome. Hum Reprod. 7:1992;597-600.
11. Navot D., Bergh P.A., Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies prevention and treatment . Fertil Steril. 58:1992;249-261.
12. Blankstein J., Shalev J., Saadon T., Kukia E.E., Rabinovici J., Pariente C., et al. Ovarian hyperstimulation syndrome prediction by number and size of preovulatory ovarian follicles . Fertil Steril. 47:1987;597-602.
13. Schmidt L.L., Asch R.J., Frederick J.L., Rojas F.J., Stone S.C., Balmaceda J.P. Predictive value of a single beta human chorionic gonadotropin level in pregnancies achieved by assisted reproduction techniques. Fertil Steril. 62:1994;333-338.
14. Guth B., Hudelson J., Higbie J., Solomon B., Polley S., Thomas S., et al. Predictive value of hCG level 14 days after embryo transfer. J Assist Reprod Genet. 12:1995;13-14.
15. Mathur R.S., Bansal A.S., Jenkins J.M. The possible role of the immune system in the aetiopathogenesis of ovarian hyperstimulation syndrome. Hum Reprod. 12:1997;2629-2634.
16. Delvigne A., Vandromme J., Demeestere I., Leroy F. Unpredictable cases of complicated ovarian hyperstimulation in IVF. Int J Fertil. 42:1997;268-270.
17. Sher G., Zouves C., Feinman M., Maassarani G. "Prolonged coasting" an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization . Hum Reprod. 10:1995;3107-3109.
18. Shoham Z., Weissman A., Barash A., Borenstein R., Schachter M., Insler V. Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program a prospective, randomized, placebo controlled study . Fertil Steril. 62:1994;137-142.
19. Shalev E., Giladii Y., Matilsky M., Ben-Ami M. Decreased incidence of severe ovarian hyperstimulation syndrome in high risk in-vitro fertilization patients receiving intravenous albumin a prospective study . Hum Reprod. 10:1995;1373-1376.
20. Agrawal R., Tan S.L., Wild S., Sladkevicius P., Engmann L., Payne N., et al. Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome. Fertil Steril. 71:1999;287-293.
21. Ludwig M., Jelkmann W., Bauer O., Diedrich K. Prediction of severe ovarian hyperstimulation syndrome by free vascular endothelial growth factor concentration on the day of human chorionic gonadotropin administration. Hum Reprod. 14:1999;2437-2441.